Chaffee Royalties -- An Update!
We revisit three Chaffee Royalty stocks and weigh in on reader mail about portfolio allocations and the differences between the Mayer’s Special Situations and Capital & Crisis portfolios.
Don’t let the next Special Situation pass you by! Chris Mayer logs air miles and meets company insiders so you don’t have to. Join Mayer’s Special Situations and get his latest stock recommendation right away.
Already a subscriber?Login
to get instant access
about this subscription
Other Readers of Mayer's Special Situations Also Benefit From these Articles
Are you “ready for Hillary?” Well, you’d better be ready by January 2017, because like it or not, factors are aligning to propel Hillary Rodham Clinton to the White House as the 45th President of the United States. What can you do to be ready? I have lots of proven ideas…
Up until now, this company has been a “one hit wonder.” It's a biotech company with a single drug in development. It's an important drug, though, one for treating a rare genetic disorder. It's in the late stages, where a flurry of paperwork is submitted to regulatory authorities for marketing approval and the Washington deciders decide. Right now, it's a waiting game in both Europe and the U.S.
By now you know that the dollars you hold just don’t hold their value thanks the government’s decades-long war against sound money, something I expect to get worse under another Clinton presidency. But there’s a way out of the dollar’s downward spiral. I’ll show you how easy it is to invest in, and the best ways to go about it…